[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AR092899A1 - Uso de masitinib para el tratamiento del cancer en subpoblaciones de pacientes identificados que utilizan factores de prediccion - Google Patents

Uso de masitinib para el tratamiento del cancer en subpoblaciones de pacientes identificados que utilizan factores de prediccion

Info

Publication number
AR092899A1
AR092899A1 ARP130103596A ARP130103596A AR092899A1 AR 092899 A1 AR092899 A1 AR 092899A1 AR P130103596 A ARP130103596 A AR P130103596A AR P130103596 A ARP130103596 A AR P130103596A AR 092899 A1 AR092899 A1 AR 092899A1
Authority
AR
Argentina
Prior art keywords
cancer
masitinib
populations
sub
treatment
Prior art date
Application number
ARP130103596A
Other languages
English (en)
Inventor
Pierre Kinet Jean
- Piquemal David Moussy Alain
Original Assignee
Ab Science
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ab Science filed Critical Ab Science
Publication of AR092899A1 publication Critical patent/AR092899A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Reivindicación 1: Un método para el tratamiento del cáncer en un paciente humano, caracterizado porque dicho método comprende administrar a un paciente humano que lo necesita al menos un inhibidor de tirosina quinasa, inhibidor de mastocitos o inhibidor de c-Kit.
ARP130103596A 2012-10-04 2013-10-04 Uso de masitinib para el tratamiento del cancer en subpoblaciones de pacientes identificados que utilizan factores de prediccion AR092899A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP12306214 2012-10-04

Publications (1)

Publication Number Publication Date
AR092899A1 true AR092899A1 (es) 2015-05-06

Family

ID=47073382

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130103596A AR092899A1 (es) 2012-10-04 2013-10-04 Uso de masitinib para el tratamiento del cancer en subpoblaciones de pacientes identificados que utilizan factores de prediccion

Country Status (20)

Country Link
US (1) US10238649B2 (es)
EP (1) EP2903616B8 (es)
JP (1) JP6234466B2 (es)
KR (1) KR102149483B1 (es)
CN (1) CN104968347A (es)
AR (1) AR092899A1 (es)
AU (1) AU2013326463B2 (es)
BR (1) BR112015007144A2 (es)
CA (1) CA2886979C (es)
DK (1) DK2903616T3 (es)
EA (1) EA037368B1 (es)
ES (1) ES2656640T3 (es)
IL (1) IL238107B (es)
MX (1) MX369999B (es)
NZ (1) NZ706420A (es)
SG (1) SG11201502626PA (es)
SI (1) SI2903616T1 (es)
TW (1) TWI609686B (es)
WO (1) WO2014053650A1 (es)
ZA (1) ZA201503054B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160244845A1 (en) * 2013-10-04 2016-08-25 Ab Science Method for determining the prognosis of pancreatic cancer
MX2016014574A (es) * 2014-05-08 2017-02-23 Oncoethix Gmbh El uso de compuestos de tienotriazolodiazepina para el tratamiento de cancer de mama triple-negativo.
WO2016062267A1 (zh) * 2014-10-24 2016-04-28 朗齐生物医学股份有限公司 奈必洛尔在制备抑制癌症的医药组合物中的用途
WO2016162229A1 (en) 2015-04-10 2016-10-13 Capsugel Belgium N.V. Abiraterone acetate lipid formulations
TWI825834B (zh) 2016-03-02 2023-12-11 日商衛材R&D企管股份有限公司 基於艾日布林之抗體-藥物結合物及使用方法
US10092564B2 (en) * 2016-03-25 2018-10-09 Ab Science Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation
CN107267454A (zh) * 2016-04-07 2017-10-20 北京京蒙高科干细胞技术有限公司 一种脐血nk细胞的体外扩增方法及其试剂盒与应用
US11040027B2 (en) 2017-01-17 2021-06-22 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
SG11201907023UA (en) * 2017-02-01 2019-08-27 Beyondspring Pharmaceuticals Inc Method of reducing neutropenia
WO2019152719A1 (en) 2018-01-31 2019-08-08 Deciphera Pharmaceuticals, Llc Combination therapy for the treatment of mastocytosis
US20210398672A1 (en) * 2018-10-29 2021-12-23 Northwestern University Big Data-Driven Personalized Management of Chronic Pain
WO2020115108A1 (en) * 2018-12-06 2020-06-11 Sørlandet Sykehus Hf Egfr inhibitors and their use in the treatment of neuroathic pain
WO2020115261A1 (en) * 2018-12-07 2020-06-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating melanoma
CN114214396A (zh) * 2020-06-30 2022-03-22 宁波市康宁医院(宁波市精神疾病预防控制中心、宁波市微循环与莨菪类药研究所) Gabrd甲基化作为抗海洛因复吸靶点的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1525200B1 (en) 2002-08-02 2007-10-10 AB Science 2-(3-aminoaryl)amino-4-aryl-thiazoles and their use as c-kit inhibitors
US8450302B2 (en) * 2002-08-02 2013-05-28 Ab Science 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors
WO2007015935A2 (en) * 2005-07-29 2007-02-08 Bayer Healthcare Llc Diagnostic methods for the prediction of therapeutic success, recurrence free and overall survival in cancer therapy
WO2008115300A1 (en) 2006-12-01 2008-09-25 Apocell, Inc. C-kit phosphorylation in cancer
EP2117531B1 (en) 2007-01-12 2016-11-02 AB Science Combination treatment of solid cancers with antimetabolites and tyrosine kinase inhibitors
WO2008098949A2 (en) 2007-02-13 2008-08-21 Ab Science Process for the synthesis of 2-aminothiazole compounds as kinase inhibitors
US20120264639A1 (en) 2009-11-04 2012-10-18 Jen Jen Yeh Methods and compositions for predicting survival in subjects with cancer
TW201130830A (en) * 2010-02-01 2011-09-16 Ab Science Combined treatment of pancreatic cancer with gemcitabine and masitinib
WO2012170640A1 (en) * 2011-06-07 2012-12-13 The Trustees Of Columbia University In The City Of New York Methods and compositions for trail-drug combination therapy

Also Published As

Publication number Publication date
US10238649B2 (en) 2019-03-26
CN104968347A (zh) 2015-10-07
SG11201502626PA (en) 2015-05-28
US20150272945A1 (en) 2015-10-01
TW201414475A (zh) 2014-04-16
MX2015004264A (es) 2015-10-12
WO2014053650A1 (en) 2014-04-10
JP2015532296A (ja) 2015-11-09
EP2903616A1 (en) 2015-08-12
MX369999B (es) 2019-11-28
BR112015007144A2 (pt) 2017-12-12
EA037368B1 (ru) 2021-03-19
EP2903616B1 (en) 2017-12-13
NZ706420A (en) 2018-08-31
EA201500373A1 (ru) 2016-02-29
AU2013326463A1 (en) 2015-04-16
EP2903616B8 (en) 2018-02-07
IL238107B (en) 2018-03-29
CA2886979C (en) 2021-01-05
ZA201503054B (en) 2016-11-30
JP6234466B2 (ja) 2017-11-22
AU2013326463B2 (en) 2018-01-18
TWI609686B (zh) 2018-01-01
DK2903616T3 (da) 2018-01-29
KR102149483B1 (ko) 2020-08-28
ES2656640T3 (es) 2018-02-27
SI2903616T1 (en) 2018-02-28
KR20150092739A (ko) 2015-08-13
CA2886979A1 (en) 2014-04-10

Similar Documents

Publication Publication Date Title
AR092899A1 (es) Uso de masitinib para el tratamiento del cancer en subpoblaciones de pacientes identificados que utilizan factores de prediccion
PH12015502042A1 (en) Use of linagliptin in cardio-and renoprotective antidiabetic therapy
BR112015026006A2 (pt) métodos para o tratamento de câncer com o uso de terapia de combinação com inibidor de cinase tor
MX2020012165A (es) Derivados de bencimidazol como inhibidores de tirosina cinasa erbb para el tratamiento del cancer.
NI201400095A (es) Metodos para el tratamiento del cáncer de pulmon de celulas no pequeñas utilizando terapia combinada de inhibidor tor cinasa.
BR112015026297A2 (pt) terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer
EA201490194A1 (ru) Комбинированная терапия, включающая ингибитор cdk4/6 и ингибитор pi3k для применения в лечении рака
CL2016000373A1 (es) Beneficio de supervivencia en pacientes con tumores sólidos con niveles elevados de proteína c reactiva
BR112017019738A2 (pt) macrociclos peptidomiméticos e usos dos mesmos
BR112015012295A8 (pt) Uso de um inibidor de wee1, e, kit para identificar um paciente com câncer
MX2020004023A (es) Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia.
SG10201902664RA (en) Combination therapy for treating cancer
BR112015011933A2 (pt) composições bacterianas sinérgicas e métodos de produção e uso das mesmas
EA201201186A1 (ru) ИСПОЛЬЗОВАНИЕ ErbB3 ИНГИБИТОРОВ В ЛЕЧЕНИИ ТРИЖДЫ НЕГАТИВНОГО И БАЗАЛЬНО-ПОДОБНОГО ВИДОВ РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ
BR112015026247A2 (pt) métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor
BR112017005598A2 (pt) macrociclos peptidomiméticos e usos dos mesmos
NI201400111A (es) Tratamiento del cáncer con inhibidores tor cinasa
CL2015003343A1 (es) Composición farmacéutica que comprende un agente terapéutico modificado en base a hemoglobina, para el tratamiento para tratar el cáncer, e imágenes de diagnóstico.
CL2016001076A1 (es) (aza) piridopirazolopirimidinonas e indazolopirimidinonas como inhibidores de fibrinolosis.
ECSP16008797A (es) Derivados de heterobicicloaril como inhibidores rorc2 y métodos de uso de los mismos
BR112015010039A2 (pt) tratamento de câncer com pomalidomida em um individuo com disfunção renal
MY176599A (en) Treatment of prostate cancer with tor kinase inhibitors
BR112018008931A8 (pt) ?compostos para tratamento de distúrbios hipoproliferativos?
EA201690376A1 (ru) Ингибиторы дезоксицитидинкиназы
BR112013024525A2 (pt) compostos, composição farmacêutica e métodos para tratar condição pré-cancerosa ou câncer em mamífero, pacientes com doença inflamatória crônica ou doença neurodegenerativa e para preparar compostos e usos de compostos e de composição farmacêutica

Legal Events

Date Code Title Description
FB Suspension of granting procedure